Summary
Background
This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Atibuclimab, making it ideal for research use. Atibuclimab is a chimeric monoclonal antibody composed of murine variable regions and a human IgG4 Fc region. It targets CD14, a key pattern recognition receptor involved in the detection of pathogen-associated molecular patterns (PAMPs) as part of the innate immune response. CD14 functions as a co-receptor for bacterial lipopolysaccharide (LPS), forming a complex with TLR4 and MD-2 to initiate pro-inflammatory signaling in response to Gram-negative bacterial components. CD14 is highly expressed on monocytes and macrophages, and is less abundantly expressed on neutrophils. It exists in both membrane-bound (mCD14) and soluble (sCD14) forms. Engagement of CD14 by PAMPs such as LPS triggers a cascade of downstream events that result in the production of cytokines including TNF-α, IL-1β, and IL-6. Atibuclimab binds to CD14 and blocks its interaction with LPS, reducing activation of the TLR4 signaling pathway and limiting the inflammatory response. Atibuclimab has been investigated for the treatment of systemic inflammatory conditions, including sepsis, acute lung injury, and cytokine-mediated disorders. This biosimilar antibody is well-suited for studying CD14-mediated signaling, innate immunity, monocyte/macrophage activation, and mechanisms of anti-inflammatory intervention.
